A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.
机构：[1]Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China[2]Zhongshan Hospital, Fudan University, Shanghai, China[3]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[4]Beijing 301 PLA Hospital, Beijing, China[5]Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[6]PLA Cancer Center of Nanjing Bayi Hospital, Nanjing, China[7]Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China[8]Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[9]Jilin Provincial Cancer Hospital, Changchun, China[10]Heilongjiang Provincial Cancer Hospital, Harbin, China[11]Hebei Tumor Hospital, Shijiazhuang, China河北医科大学第四医院肿瘤内科临床科室[12]Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China[13]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research under Ministry of Education, Peking University Cancer Hospital, Beijing, China
Gong Jifang,Liu Tianshu,Fan Qingxia,et al.A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.[J].JOURNAL OF CLINICAL ONCOLOGY.2014,32(3):doi:10.1200/jco.2014.32.3_suppl.102.
APA：
Gong, Jifang,Liu, Tianshu,Fan, Qingxia,Bai, Li,Bi, Feng...&Shen, Lin.(2014).A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity..JOURNAL OF CLINICAL ONCOLOGY,32,(3)
MLA：
Gong, Jifang,et al."A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.".JOURNAL OF CLINICAL ONCOLOGY 32..3(2014)
医学